Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Mylan has waived its exclusive rights to generic Kaletra (lopinavir / ritonavir) in the US to aid wider access in case the medication would be effective Covid-19 therapies.
The waiver will enable other generics to be eligible for the US Food and Drug Administration (FDA) approval for treating patients in the country, to expand availability when additional clinical trials or other evaluations demonstrate that the product could be an effective Covid-19 treatment.
Last week, Mylan announced the restart of manufacture of hydroxychloroquine sulfate tablets at its facility in the US to cater to demand that could result if the product is proven effective in